9.19
+4.08%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Newron Pharmaceuticals SpA
Its shares trade on SIX under the ticker NWRN.SW. It has been listed since 12 December 2006. In the fiscal year to 31 December 2025, it reported revenue of €19.1m and a net loss of €13.2m. At that date it held total assets of €40.0m and shareholders' equity of −€11.1m.
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Dec 2006
- Employees
- 26
- Website
- newron.com ↗
Leadership
Pay as last reported
- Dr. Chris MartinChairman of the Board, since 2025
- Prof. Stefan WeberChief Executive Officer, Executive Director, since 2005€504,000
- Mr. Roberto GalliChief Financial Officer
- Mr. Filippo MoriggiaVice President - Operations
- Mr. Dennis DionneVice President - Commercial Affairs
- Ms. Laura FaravelliVice President - Business Development
- Dr. Ravi AnandChief Medical Officer€1.3m
- Dr. Luca BenattiNon-Executive Independent Director, since 1998€72,000
- Ms. Margarita ChavezNon-Executive Independent Director€69,000
- Ms. Gillian DinesNon-Executive Independent Director€86,000
- Mr. Patrick LangloisNon-Executive Independent Director€88,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 50
- Social
- 77
- Governance
- 54
- Women in the workforce
- 41%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong research and development capabilities, allowing for innovative drug discovery and development.
- Robust pipeline with several promising drug candidates in various stages of development.
- Well-established partnerships with leading pharmaceutical companies, providing access to additional resources and expertise.
- Solid financial position and stable revenue streams, enabling investment in future growth.
Weaknesses
- Relatively small market presence compared to established pharmaceutical companies.
- Limited product portfolio with dependence on the success of a few key drug candidates.
- Vulnerability to regulatory changes and stringent approval processes in the pharmaceutical industry.
- Potential difficulty in attracting top talent due to competition from larger pharmaceutical companies.
Opportunities
- Growing demand for innovative and effective treatments in various therapeutic areas.
- Expansion into emerging markets with untapped potential and less competition.
- Strategic collaborations and partnerships to enhance research capabilities and market reach.
- Adoption of digital technologies and data analytics to drive research and personalized medicine.
Threats
- Intense competition from established pharmaceutical companies with greater resources and market presence.
- Uncertainty surrounding regulatory approvals and patent protection for drug candidates.
- Potential pricing pressures and reimbursement challenges in healthcare systems.
- Risks associated with clinical trials, including unexpected adverse events and delays.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.